Answer
Patients with chronic hepatitis B or C receiving combination antiretroviral therapy containing raltegravir have an increased risk of severe, potentially fatal hepatic adverse reactions; liver function should be monitored according to standard practice, with treatment interruption or discontinuation considered if liver disease worsens.
Sources for this answer
- Isentress 400 mg Film-coated TabletsMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 37Document updated
Sources checked